The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a greater substantial decrease